Wake Forest University Health Sciences
The purpose of this study is to evaluate the use and functionality of virtual reality (VR) during radiation therapy treatments for patients with prostate, breast, lung, or head and neck cancer.
This is a randomized controlled trial that will assess the feasibility, acceptability, tolerability, and initial clinical efficacy of using a VR device during radiation therapy for participants with prostate cancer, breast cancer, lung cancer, or head and neck cancer. Participants will be randomized 2:1 to either the VR device intervention arm or the standard of care control arm. Participants will undergo pre-study assessments, assessments before and after the first radiation treatment, every 6th radiation treatment, and at the end of treatment.
Patients: Inclusion Criteria: * Participants planned for radiation therapy for 15 or more treatments with non-neutron generating energies (10 MV or less) per study PI for prostate, breast, lung, or head and neck cancer. Neutrons have the potential to damage the VR headset device and are generated for energies above 10 MV. * Age 18 years or older at the time of consent. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-33 or Karnofsky (KPS) 30-100 at the time of enrollment. * Ability to understand and the willingness to sign an IRB-approved informed consent document directly…
Radiation therapy for prostate cancer, breast cancer, lung cancer, or head and neck cancer.
Participants will wear the VR headset (Meta Quest 2) during standard of care radiation therapy
Radiation therapists will be asked about their experiences and proficiency with using the VR device.
Arctuva estimate
Verify or correct the compensation shown for this listing.